Clinical trials: Cancer of the Esophagus
Esophageal Neoplasms
Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial
The standard non surgical therapy of locally advanced esophageal cancer is based on a definitive concurrent chemoradiotherapy regimen with fluorouracil and cisplatin.
- Trial name
- NCT00213486
- Testing
- irinotecan
- Where
- France
- Volunteers
- 43 people
- Sponsor
- University Hospital, Rouen
Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy.
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response, Deep Learning
- Trial name
- DL-ESCC (NCT07088354)
- Testing
- The high-throughput extraction of large amounts of quantitative image features from medical images
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Esophageal Cancer
Comparison of Subtotal Stomach and Narrow Gastric Tube After Esophagectomy
Currently, both the subtotal stomach and narrow gastric tube approaches are widely used for esophagogastric anastomosis after esophagectomy.
- Trial name
- NCT05342805
- Testing
- Narrow gastric tube
- Where
- Vietnam
- Volunteers
- 50 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Esophageal Squamous Carcinoma
Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC
This is a single-arm, exploratory clinical study.
- Trial name
- NCT07490002
- Testing
- Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxel
- Volunteers
- 33 people
- Sponsor
- Changhai Hospital
Breast Cancer, Lung Cancer
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor…
- Conditions
- Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer
- Trial name
- TRT-001 (NCT02960594)
- Testing
- INO-1400, INO-9012, INO-1401
- Where
- 6 sites in United States
- Volunteers
- 93 people
- Sponsor
- Inovio Pharmaceuticals
Advanced Esophagus Cancer
Apatinib as First -Line Treatment for Advanced Esophagus Cancer
An Exploratory study of Amapinib for patients with advanced esophagus cancer .
- Trial name
- NCT03542422
- Testing
- Apatinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
Cancer-related Fatigue, Survival
PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer
The primary objective of this study is to evaluate the efficacy of PG2 concurrent with concurrent chemoradiation therapy (CCRT) for relieving fatigue among locally advanced esophageal cancer patients who are under preoperative…
- Conditions
- Cancer-related Fatigue, Survival, Tumor, Esophageal
- Trial name
- NCT03611712
- Testing
- Astragalus Polysaccharides 500 mg
- Where
- 4 sites in Taiwan
- Volunteers
- 48 people
- Sponsor
- PhytoHealth Corporation
Esophageal Neoplasms
A Trial to Compare Preoperative Chemoradiation and Surgery Versus Surgery Alone in Squamous Cell Carcinoma of Oesophagus
Carcinoma of the esophagus is the among the most common cancers in Indian population. While adenocarcinoma is more common in western countries, in India squamous cell carcinoma is the more frequent form.
- Trial name
- NCT01151839
- Testing
- Esophagectomy, Neoadjuvant chemoradiation followed by surgery
- Where
- India
- Volunteers
- 100 people
- Sponsor
- All India Institute of Medical Sciences
Gastrointestinal Cancer, Colorectal Cancer
Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy
This randomized, controlled, pilot experiment will evaluate the effects of an aerobic walking intervention on OIPN (oxaliplatin-induced peripheral neuropathy) in patients with gastrointestinal (GI) cancer who are already…
- Conditions
- Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Cancer, Gastric Cancer
- Trial name
- NCT03515356
- Testing
- MI-Walk Intervention, Physical Activity Education Pamphlet
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of Michigan Rogel Cancer Center
Gastric-Esophageal Cancer
Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
The goal of this clinical trial is to assess if circulating tumor DNA, as assessed by Signatera tumor-informed MRD assay, can guide de-escalation of adjuvant therapy in patients with resectable Stage II-IVa…
- Trial name
- SIGNAL GEC-101 (NCT07565857)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 1,000 people
- Sponsor
- Natera, Inc.
Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
The purpose of this study was to evaluate the safety, feasibility and outcome of anti-PD-1 antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by minimally…
- Trial name
- iCROSS (NCT04973306)
- Testing
- Neoadjuvant Chemoradiotherapy, Tislelizumab, Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Solid Tumor
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06112704
- Testing
- HS-20093
- Where
- 21 sites in China
- Volunteers
- 220 people
- Sponsor
- Hansoh BioMedical R&D Company
Barrett Esophagus, Esophageal Adenocarcinoma
A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study
The investigators aim to study the rate of developing a biopsy-based diagnosis of high-grade dysplasia (HGD) and EAC in BE patients in a prospective cohort of 208 BE patients at high risk of progression (i.e.
- Conditions
- Barrett Esophagus, Esophageal Adenocarcinoma, Diagnosis
- Trial name
- WATSEURO2 (NCT05642338)
- Testing
- WATS3D
- Where
- Netherlands
- Volunteers
- 416 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Esophageal Cancer, Reflux, Gastroesophageal
Evaluating Acid Reflux After Oesophageal Stenting Using Anti-reflux Stents
Incurable oesophageal cancer remains a global problem and in South Africa the vast majority of patients with oesophageal cancer have advanced disease at first presentation and are not curable.
- Trial name
- NCT05303298
- Testing
- Anti-reflux oesophageal stent, Conventional oesophageal stent
- Where
- South Africa
- Volunteers
- 72 people
- Sponsor
- University of Cape Town
Esophagus Cancer
Functional Imaging to Identify Radiosensitive Esophageal Cancer - a Biomarker Validation Study
This trial on biomarker validation investigates the use of innovative re-staging FDG-PET parameters to detect highly chemoradiation (CRT) sensitive squamous cell carcinomas of the esophagus (SCEC) at the end of preoperative or…
- Trial name
- FIRASE (NCT06189898)
- Testing
- Re Staging FDG-PET
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Sebastian Zschaeck
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
To investigate the effects of the combination of two chemotherapies followed by immunostimulants on the interferon gamma expression and infiltration of cytotoxic T cells in the tumour microenvironment in patients with previously…
- Trial name
- AuspiCiOus (NCT05177133)
- Testing
- Capecitabine, Oxaliplatin, Retifanlimab
- Where
- 8 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Esophageal Cancer, Gastric Cancer
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524186
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Barrett's Esophagus, Early Esophageal Adenocarcinoma
The Effect of Ablation Therapy on Barrett's Esophagus
To assess the effect of ablative therapy (Photodynamic Therapy or Radiofrequency ablation ) on Barrett's Esophagus
- Trial name
- ablation IN BE (NCT00587314)
- Testing
- Biopsy
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Mayo Clinic
Esophageal Squamous Cell Carcinoma
Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of anlotinib combined with sindilimab as second-line treatment for advanced esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT04813406
- Testing
- Anlotinib + Sintilimab
- Volunteers
- 53 people
- Sponsor
- Henan Provincial People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.